Generic Medicine Info
Indications and Dosage
Plaque psoriasis
Adult: Initially, 160 mg once, then followed by 80 mg once every 2 weeks for 6 doses (at weeks 2, 4, 6, 8, 10 and 12). Maintenance: 80 mg every 4 weeks. Consider treatment discontinuation if there is no response after 16-20 weeks.

Psoriatic arthritis
Adult: Patient who are intolerant to previous disease-modifying antirheumatic drugs (DMARDs) therapy: As monotherapy or in combination with a DMARD (e.g. methotrexate): Initially, 160 mg once, then followed by 80 mg every 4 weeks. Consider treatment discontinuation if there is no response after 16-20 weeks. Patient with concomitant moderate to severe plaque psoriasis, follow dosing guidelines for plaque psoriasis.
Hypersensitivity. Active infection (e.g. TB). Pregnancy. Administration of live vaccine.
Special Precautions
Patients with chronic or recurrent infection and inflammatory bowel disease (e.g. Crohn’s disease, ulcerative colitis). Lactation.
Adverse Reactions
Significant: Hypersensitivity reactions (e.g. urticaria, angioedema, anaphylaxis), infections (e.g. upper respiratory tract infection, oral candidiasis, conjunctivitis, tinea infections).
Blood and lymphatic system disorders: Neutropenia, thrombocytopenia.
Gastrointestinal disorders: Nausea.
General disorders and administration site conditions: Inj site reactions (e.g. erythema, pain).
Infections and infestations: Herpes simplex (mucocutaneous), influenza, cellulitis.
Respiratory, thoracic and mediastinal disorders: Oropharyngeal pain, upper respiratory tract infection, rhinitis.
Skin and subcutaneous tissue disorders: Rash, urticaria, eczema.
Monitoring Parameters
Monitor for hypersensitivity reactions, signs and symptoms of infection, active TB (during and after treatment) and inflammatory bowel disease.
Drug Interactions
Potentially Fatal: May enhance the adverse effects and diminish the therapeutic effect of live vaccines.
Description: Ixekizumab is a humanised immunoglobulin G4 (IgG4 kappa) monoclonal antibody that selectively binds with the interleukin 17A (IL-17A), a cytokine involved in normal inflammatory and immune responses, thus inhibiting the release of proinflammatory cytokines and chemokines.
Absorption: Bioavailability: 60-81%. Time to peak plasma concentration: Approx 4 days.
Distribution: Crosses placenta. Volume of distribution steady-state: 7.1 L.
Metabolism: Expected to be degraded into small peptides and amino acids via catabolic pathways.
Excretion: Elimination half-life: 13 days.
Store between 2-8°C or below 30°C for up to 5 days. Do not freeze. Protect from light. Any unused portion should be disposed of in accordance with local requirements.
MIMS Class
Psoriasis, Seborrhea & Ichthyosis Preparations
ATC Classification
L04AC13 - ixekizumab ; Belongs to the class of interleukin inhibitors. Used as immunosuppressants.
Anon. Ixekizumab. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 07/08/2019.

Anon. Ixekizumab. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 07/08/2019.

Buckingham R (ed). Ixekizumab. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 07/08/2019.

Joint Formulary Committee. Ixekizumab. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 07/08/2019.

Taltz Injection Solution (Eli Lilly and Company). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 07/08/2019.

Disclaimer: This information is independently developed by MIMS based on Ixekizumab from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in